Proteomics
Celera has developed proprietary techniques for capturing cell surface proteins
and best-of-class mass spectrometry and informatics platforms for identifying and quantifying those proteins. The Celera proteomics platform is:
- Flexible
- To date we have worked in pancreatic, lung, colon, breast, gastric, prostate and renal cancers. Our proteomics platform is amenable to other areas of oncology or any disease area where protein differentials between sets of samples could identify therapeutic or diagnostic targets.
- Robust
- We have a vibrant pipeline of targets, ranging from early discovery, through RNAi and IHC validation, to pre-clinical development with external partners. These targets are suitable for diagnostics, therapeutics, and in vivo imaging.
- Successful
- To date partners have selected seven Celera targets to take forward into their drug development programs.
Celera has demonstrated the capability of its proteomics target discovery platform by identifying differentially expressed proteins on the surface of pancreatic cancer cells. These proteins are undergoing further validation to confirm their viability as targets. The proteomics effort is currently focused on pancreatic cancer, lung cancer, colon cancer, and breast cancer.
Informatics and Computing
Informatics played a critical role in managing the data from the human genome, and the conversion of that raw sequence data into the assembled genome sequence. These capabilities are now being applied to proteomic analysis for both diagnostic and drug discovery.
